23 May, 2026
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on…
WASHINGTON — A group of Senate Democrats is proposing that Medicare cover in-home care, which would create the first new benefit in the program since the Part D retail drug…
The Trump administration has made sweeping changes to vaccine policy over the past year justified by invocations of patients’ “personal autonomy.” In January, Department of Health and Human Services head…
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Shelley Wood and Eric Topol. Be sure to sign up for the weekly “First Opinion Podcast”…
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on…

Slot Deposit Pulsa Tanpa Potongan Buat Kamu yang Praktis

Bermain slot online kini semakin mudah berkat deposit pulsa tanpa potongan. Kamu tidak perlu repot memakai rekening bank atau e-wallet—cukup isi pulsa dari HP, dan saldo langsung masuk penuh ke akun game. Praktis banget untuk semua pemain, pemula maupun berpengalaman. Apa Itu Deposit Pulsa Tanpa Potongan? Deposit pulsa tanpa potongan adalah metode top-up saldo game […]

1 min read

Leucovorin’s promise for autism demands real-world proof

Something remarkable, and controversial, is unfolding in American medicine. The Food and Drug Administration says it is fast-tracking leucovorin, a long-established drug, for potential use in treating cerebral folate deficiency, a condition connected to the presence of folate receptor autoantibodies estimated to be present in up to 76% of children diagnosed with autism. Like many […]

6 mins read

STAT readers weigh in on massive health care profits

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a […]

25 mins read

I’m stuck in the gray market for GLP-1s

On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, the announcement sent Novo Nordisk and Eli Lilly stocks tumbling. For patients who’ve been priced out, that […]

10 mins read